News | May 20, 2015

Data Show Remote Monitoring Technologies Significantly Lower Healthcare Costs, Hospitalizations

St. Jude Medical study finds remote monitoring cuts 10 hospitalizations, 119,000 hospital days and more than $370,000 per 100 patients

St. Jude Medical, Merlin, remote monitoring, lower costs, hospitalizations, HRS

May 20, 2015 — New data from St. Jude Medical found that patients with cardiac devices who use remote monitoring have significantly fewer hospitalizations and lower overall healthcare costs than patients who do not. The data was presented during a late-breaking clinical trial session during Heart Rhythm 2015, the Heart Rhythm Society’s annual scientific sessions. The findings were a result of a five-year study, one of the largest to date on remote monitoring technologies.

“This study is the first of its kind to find an economic benefit when remote monitoring is utilized in pacemaker, defibrillator and cardiac resynchronization patients in the U.S.,” said Jonathan Piccini, M.D., associate professor of medicine at Duke University Medical Center in Durham, North Carolina. “Use of remote monitoring is associated with lower risks of hospitalization, shorter hospital stays, and lower rates of heart failure and stroke hospitalization. Additionally, since fewer than half of cardiac device patients currently use remote monitoring, our findings suggest a significant opportunity for quality improvement. These important observations should have significant implications for patient management, as well as costs to the healthcare system.”

The study, which obtained data from a real-world setting, reinforces the important role of remote monitoring in improving the overall care of patients treated with implantable cardiac devices. Researchers analyzed data from more than 90,000 patients with pacemakers, implantable cardioverter defibrillators (ICDs), and cardiac resynchronization therapy (CRT) devices. The data showed that remote monitoring with systems, such as the St. Jude Medical Patient Care Network (PCN), eliminates 10 hospitalizations and 119 hospital days and resulted in cost savings of more than $370,000 per 100 patients annually.

The findings offer additional evidence of the benefits of remote monitoring. In a study presented at last year’s Heart Rhythm Society meeting, and recently published in the Journal of the American College of Cardiology, St. Jude Medical found improved survival rates of patients using the company’s Merlin.netPCN. Patients with high adherence to remote monitoring had more than twice (2.4x) the probability of survival than that of patients without remote monitoring. High adherence was measured as weekly transmissions of patient data from the [email protected] transmitter to the PCN at least 75 percent of the time. Recommendations for remote monitoring technologies were recently updated and published by the Heart Rhythm Society.

“Recent data surrounding remote monitoring technologies have been important to advancing the understanding of the benefits these systems provide,” said Niraj Varma, M.D., electrophysiologist at the Cleveland Clinic in Cleveland, OH. “The updated recommendations announced recently by the Heart Rhythm Society reflect the findings from these important studies and highlight the importance of using remote monitoring systems to improve the consistency of follow-up care for patients. We will continue to work with industry to further reinforce how utilization of the remote monitoring systems can improve clinical outcomes for patients around the world.”

For more information:

Related Content

FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
Overlay Init